A Hypothesis Concerning the Biphasic Dose-response of Tumors to Angiostatin and Endostatin

George E. Parris

Abstract
This manuscript proposes a hypothesis to explain the U-shaped dose-response observed for angiostatin and other high-molecular-weight drugs in various anti-cancer bio-assays. The dose-response curves for angiostatin and endostatin (measured as suppression of tumor growth) go through an optimum (i.e., minimum tumor growth) and then becomes less effective at higher doses. The literature suggests that at lower doses the primary action of these high-molecular-weight drugs is to counteract the angiogenic effects of vascular endothelial growth factor (VEGF). To do this, the drugs must pass out of the blood vessel and enter the extra-cellular matrix (ECM) where VEGF induces the growth and fusion of tip cells. Ironically, VEGF actually facilitates access of the drugs to the ECM by making the vascular endothelium leaky. At higher doses, the high-molecular-weight drugs seem to reverse VEGF-induced permeability of the endothelium. Thus, at high dose rates, it is hypothesized that the drugs are not able to enter the ECM and block the angiogenic effects of VEGF there. As a result, high doses of the drugs do not suppress vascularization of the tumor or tumor growth. Moreover, if the permeability of the vessels is suppressed, the VEGF released by the stroma is concentrated in the ECM where it amplifies the angiogenic activity around the tumor.

Keywords
angiostatin, endostatin, angiogenesis, macrophage, tip cell, biphasic, dose, response, cancer, tumor, VEGF, ECM

Angiogenesis and Cancer
In the early 1980s, it was recognized that a factor secreted by tumor cells caused leakage from blood vessels and the term “vascular permeability factor” (VPF) appeared in the literature (Senger et al. 1986; Claus et al. 1990). It was also soon realized that VPF was associated with growth of blood vessels (i.e., angiogenesis) around tumors (Dvorak et al. 1991; Senger et al. 1993) and the term was changed first to “vascular permeability factor/vascular endothelial growth factor” (Senger et al. 1993) and finally to merely “vascular endothelial growth factor” (VEGF) by 1993 (Adamis et al. 1993).

Although some tumors attain nutrients by growing along existing blood vessels or otherwise coopting existing blood vessels (Dome et al. 2007; Donnem et al. 2013), by the late 1990s, it was widely accepted that conversion of hyperplasia into neoplasia is accompanied by (and facilitated by) formation of new blood vessels, i.e. an “angiogenic switch” (Hanahan and Folkman 1996; Bergers et al. 1999; Folkman 2002). Rapidly growing tumors tend to display an “aerobic glycolysis” phenotype (i.e., the Warburg effect) in which both aerobic and anaerobic respiration provide energy (Sciaccavelli et al. 2014) and proliferation is only limited by the availability of the blood supply. Sustained angiogenesis became recognized as one of the hallmarks of cancer (Hanahan and Weinberg 2000). Thus, great interest has developed in finding anti-angiogenic drugs (Folkman 1985; Folkman and Ingber 1992; Bergers et al. 1999).

The Tumor and its Stroma
Once a tumor has begun growing, inflammation and hypoxia cause the release of chemokines that attract immune cells that begin to form the stroma. VEGF/VPF isoforms are also cytokines that attract monocytes (Czepluch et al. 2011), macrophages (Li et al. 2011), pericytes (Grosskreutz et al. 1999; Yamagishi et al. 1999; Ribatti et al. 2011) and

1 Montgomery College, Department of Chemistry, Rockville, MD, USA

Corresponding Author:
George E. Parris, 9601 Warfield Road, Gaithersburg, MD 20882, USA.
Email: Antimony_121@hotmail.com

Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (http://www.uk.sagepub.com/aboutus/openaccess.htm).
fibroblasts (Senger et al. 1993; Wynn 2008; Asumda and Chase 2011) to surround the tumor. The attraction of the pericytes to the tumor apparently pulls them from the endothelial walls of the local blood vessels and makes the blood vessels hyper-permeable (i.e., leaky) (Adams and Altaylor 2007; Zhao et al. 2007; Azzi et al. 2013).

It has been found that the concentration of VEGF/VPF in the microenvironment (i.e., immediately around specific clusters of cells) rather than the bulk concentration of VEGF/VPF is what is important in determining the course of angiogenesis (Dvorak et al. 2011; Fidler 2011). In an interesting series of experiments, Blau and coworkers (Springer et al. 2003; Ozawa et al. 2004; von Degenfeld et al. 2006) created four homogeneous clones of myoblast that secreted VEGF at different levels. They found that when they used mixtures of cell clones to produce average dose rates between 5 and 70 ng VEGF/10^6 cells/day, angiogenesis was observed with formation of normal blood vessels. At gross dose rates greater than about 100 ng VEGF/10^6 cells/day, abnormal development of blood vessels occurred leading to hemangiomas. More importantly, when homogeneous clones of myoblast that produced less than 70 ng VEGF/10^6 cells/day were used, no abnormal foci or abnormal angiogenesis were observed regardless of the number of myoblast injected; and the blood vessels that were formed were not leaky, had normal pericytes and were VEGF-independent. In contrast, when individual cells producing higher dose rates of VEGF were used, the blood vessels that formed were leaky, VEGF-dependent, and malformed. Clearly, new blood vessels tend to form only very near the source of VEGF/VPF (i.e., a very steep concentration gradient) (Springer et al. 2003). This observation may be related to the way that VEGF/VPF interacts with receptors (Kiba et al. 2003a; Kiba et al. 2003b). VEGF levels are normally very tightly controlled because too little or too much VEGF can be lethal to developing embryos (Carmeliet et al. 1996; Miquerol et al. 2000).

In any event, the observations are consistent with the fact that VEGF/VPF acts locally; not systemically. The nutrient demand of rapidly growing tumors requires a blood supply that is initially provided by secretion of VEGF/VPF that dilates local blood vessels and makes them leaky. Leaky blood vessels appear to be caused by the migration of pericytes (Hasumi et al. 2007; Zhao et al. 2007; Cao and Cao 2010; Cao et al. 2010; Ribatti et al. 2011) that fill gaps between endothelial cells into the ECM.

**The Modes of Action of VEGF/VPF**

The mechanism of angiogenesis induced by VEGF/VPF is still poorly understood, but recent publications have provided some detail (Ferrara et al. 2003; Dvorak et al. 2011; Jeong et al. 2011; Ji 2011; Li et al. 2011; Ribatti et al. 2011; Tammela et al. 2011; Weis 2011; Indraccolo 2013). There seem to be two distinct activities of VEGF/VPF: (i) formation of leaks in existing vessels and (ii) formation of new vessels. In normal vessels the lumen accounts for about 30% of the vessel diameter, but under the influence of high concentrations of VEGF/VPF pericytes that maintain the integrity of normal vessels appear to be drawn away towards the tumor cells (Dvorak et al. 2011; Ribatti et al. 2011). Thus, the weakened vessels balloon outward and leak blood with macromolecules through the thin lining of endothelial cells (Dvorak et al. 1991). This effect of VEGF/VPF acts quickly (within 5 hr) but has a limited range of less than 0.5 mm from the tumor (Dvorak et al. 1991). The angiogenic effects of VEGF/VPF appear to act over greater distances (or at lower concentrations). For example, in the rabbit cornea model (Gimbrone et al. 1973) used to investigate angiogenesis, new vessels are induced to sprout many millimeters from the source of VEGF/VPF (Ryu and Albert 1979). The sprouting of new blood vessels may not begin for 1 to 10 days (Ryu and Albert 1979).

**Anti-Angiogenic Agents**

The clinical importance of biphasic angiostatic agents has recently been reviewed (Reynolds 2010).

**Formation and Composition of Angiostatin and Endostatin**

Concurrent with the establishment of angiogenesis and rapid growth of solid tumors, a variety of enzymes are used by the tumor to break down the ECM. The enzymes (e.g., matrix metalloproteinases (MMPs) and urokinase-type plasminogen activators (uPA)) cut polymers (e.g., glycosaminoglycans, proteoglycans and collagen) and proteins (e.g., plasminogen) into smaller soluble pieces (plasmin and angiostatin). Angiostatin (a 38 kDa protease fragment of plasminogen) (O'Reilly et al. 1994; Folkman 1995; Dong et al. 1997; Gately et al. 1997) was identified as a natural anti-angiogenesis agent in 1994 and was soon proven to have potent anti-tumor effects. Similarly, endostatin (a C-terminal, 20 kDa, zinc-binding protein cut from collagen XVIII) was discovered in 1997 (O'Reilly et al. 1997; Beecken et al. 2001).

**Targets of Angiostatin**

Angiostatin binds to cell surface glycoproteins, angiomotin (Troyanovsky et al. 2001), integrins (Tarui et al. 2001; Chavakis et al. 2005), ATP synthase (Moser et al. 1999; Wahl et al. 2005; Chi and Pizzo 2006; Yamamoto et al. 2007). It also binds to mitochondrial ATP synthase (Lee et al. 2009).

**Effects of Angiostatin**

Angiostatin is known to promote apoptosis (O'Reilly et al. 1994; O'Reilly 1997; Lee et al. 2009). It inhibits recruitment of macrophages (Distler et al. 2002; Chavakis et al. 2005; Dineen et al. 2008; Lee et al. 2009; Chen et al. 2011; Li et al. 2011; Lin et al. 2011), which are normally attracted into
the stroma by signaling involving VEGFR-1 and VEGFR-2 (Li et al. 2011) and which are involved with completing vascular circuits with VEGFR-3 (Tammela et al. 2011). Angiostatin has recently been shown to inhibit migration and activation of neutrophils (Aulakh et al. 2014).

**Hypothesis for Action**

One hypothesis for its mechanism of action is that angiostatin blocks the action of hepatocyte growth factor (HGF) (Wajih and Sane 2003), which activates the c-met receptor. The c-met receptor of endothelial and smooth muscle cells initiates migration and facilitates proliferation essential to establishment of new blood vessels (Chang et al. 2013). There is very active research on this pathway in a number of cancer types. The mechanism appears to be dependent on the kringle 5 (K5) domain of angiostatin which is shared with HGF (Ansell et al. 2007). The mechanism of endostatin is less studied but appears to facilitate apoptosis and suppress autophagy by modifying the effect Bcl-2 via its complex with Beclin 1 (Ramakrishnan et al. 2007; Wu et al. 2011; Ibrahim et al. 2014).

**Disappointing Clinical Results and the U-shaped Dose-Response Curve**

Following the 1996 report from the Folkman group on the preclinical effects of angiostatin (O’Reilly et al. 1996) there was much optimism that at last a “unifying concept” had been discovered for cancer treatment (Saphir 1997). Numerous candidate compounds went into clinical trials (Folkman 2003) and the ownership of intellectual property was aggressively contested (Brower 2000). But, as time passed, the dream of a universal chemotherapy for cancers began to wane as clinical trials produced less than overwhelming results (Gupta and Zhang 2005). Reynolds has provided a comprehensive review of the findings and show that a u-shaped dose-response curve may be the problem in many cases (Reynolds 2010; Javaherian et al. 2011). Here, I want to dissect the U-shaped curve into its component parts.

**A Hypothesis for U-Shaped Dose Response for Angiostatin**

Mathematically, a U-shaped curve can be derived from two S-shaped dose-response curves as indicated in Figure 1. Many biochemical mechanisms could be invoked to account for the two S-shaped curves. The key factor here seems to be that VEGF/VPF released by the tumor is known to have two distinct modes of action: It is angiogenic and it causes permeability of the nearby blood vessels. Based on our understanding of the role of VEGF/VPF in angiogenesis (discussed above), a conceptual model can be proposed (Figure 1). The first drug target (with a rather low effective dose 50%, ED50) blocks angiogenesis and inhibits tumor growth as expected. At higher doses, a second target (with higher ED50) blocks the access of the drug to the first target. This model has the virtue of requiring a minimum number of assumptions. The second target is merely nullifying the first target. Although it is easy to postulate such a model with some confidence, it is harder to demonstrate the actual biochemical processes that are being impacted by the drug.

**Discussion**

As discussed above, VEGF/VPF has very localized effects on angiogenesis (Springer et al. 2003), whereas the angiostatin and endostatin effects are systemic (i.e., they suppress angiogenesis at distant metastases) (Fisher et al. 1989a; Fisher et al. 1989b; Fisher et al. 1990). The U-shaped dose-response of angiostatin on angiogenesis is probably traceable to its different affinity and/or efficacy towards two (or more receptors).

**Low Dose Rates of Angiostatin**

The effects of angiostatin, especially interference with VEGF signaling, are believed to cause the inhibition of angiogenesis (Lee et al. 2009) consistent with the mechanism of VEGF-induced angiogenesis discussed above (Fantin et al. 2010; Fantin et al. 2011; Fantin et al. 2013; Lanahan et al. 2013; Fantin et al. 2014). This appears to be the primary effect of the angiostatic agents at low doses (dose rates).

**High Dose Rates of Angiostatin**

On the other hand, access of exogenous angiostatin (a moderate size 38kD protein) introduced from the blood stream (Kenan and Wahl 2005) into the ECM (i.e., where the new blood vessels are being formed) is facilitated by the VEGF/VPF-induced dilation (Koshida et al. 2003) and leakage (Sima et al. 2004; Shyong et al. 2007) of the existing blood vessels. At higher

![Figure 1. Two S-shaped Curves Produce a U-shaped Curve. Based on inspection of typical S-shaped curves, we estimate that the ED50 for the anti-angiogenic effect is about half-way down the slope and the ED50 for the anti-permeability effect is about at the bottom of the U.](image-url)
dose rates, angiostatin causes constriction of blood vessels (Koshida et al. 2003) and stops the leakage (Sima et al. 2004; Shyong et al. 2007), thus preventing the exogenous drug from getting into the ECM where tumor-associated macrophages are facilitating the completion of vascular circuits. It is also relevant that reduction in the permeability of the blood vessels ensures that the VEGF/VPF (protein 32-44 kDa) will be concentrated in the stroma rather than dissipated in the blood (Figure 1) and enhances angiogenesis. Hence, high doses (dose rates) actually reduce the effectiveness of angiostatin and produce a U-shaped dose-response curve (Figure 1). Endostatin seems to follow a similar pattern (Celik et al. 2005; Tjin Tham Sjin et al. 2006) for the same reasons (Brankin et al. 2005; Marneros et al. 2007).

While high doses of angiostatin appears to interrupt VEGF signaling by interacting with its receptors (VEGFR), a humanized monoclonal antibody has been designed to directly target VEGF (i.e., bevacizumab, Avastin). This VEGF antibody suppresses perfusion of water and docetaxel (molecular weight 808 g/mole) into tumors (Van der Veldt et al. 2012) presumably by preventing VEGF from reaching its receptors on pericytes (Greenberg et al. 2008). This observation is at odds with the hypothesis that “normalized” (non- leaky) blood vessels are more efficient for drug delivery to tumors (Azzi et al. 2013). It has recently been suggested (Van der Veldt et al. 2012) that introducing cytotoxic anti-cancer agents before administration of agents that suppress VEGF signaling and allows the cytotoxic agent to enter the tumor and then be trapped there (i.e., reduced clearance). Because of their size, access of blood-borne angiostatin and endostatin to the ECM may be particularly sensitive to the porosity of the blood vessels.

**Summary**

This U-shaped dose-response of angiostatin is consistent with the variety of high-molecular-weight drugs (i.e., that do not readily diffuse through tissues) that are known to have U-shaped dose response against angiogenesis (Slaton et al. 1999; Motegi et al. 2002; Panigrathy et al. 2002), and thus, could provide a universal explanation for this behavior (without specifically addressing molecular interactions, which are still poorly understood). One prediction of this hypothesis is that the angiogenic effects would be more effective at high doses if the drug did not depend on reaching the tumor via the blood vessels. Indeed, strategies using viruses to express the anti-angiogenic agents in the tumor itself have been developed and seem to work well (Shyong et al. 2007; Luo et al. 2011).

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**References**

Adams AP, Shima DT, Yeo KT, Yeo TK, Brown LF, Berse B, D’Amore PA, and Folkman J. 1993. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 193:631-638

Adams RH and Alitalo K. 2007. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464-478

Ansell PJ, Zhang H, Davidson DJ, Harlan JE, Xue J, Brodjian S, Lesniewski R, and McKeegan E. 2010. Recombinant kringel 5 from plasminogen antagonises hepatocyte growth factor-mediated signalling. Eur J Cancer 46:966-973

Asumda FZ and Chase PB. 2011. Age-related changes in rat bone marrow mesenchymal stem cell plasticity. BMC Cell Biol 12:44

Aulakh GK, Balachandran Y, Liu L, and Singh B. 2014. Angiostatin inhibits activation and migration of eutrophils. Cell Tissue Res 355:375-396

Azzi S, Hebda JK, and Gavard J. 2013. Vascular permeability and drug delivery in cancers. Front Oncol 3:211

Beecken WD, Fernandez A, Joussen AM, Achilles EG, Flynn E, Lo KM, Gillies SD, Javaherian K, Folkman J, and Shing Y. 2001. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J Natl Cancer Inst 93:382-387

Bergers G, Javaherian K, Lo KM, Folkman J, and Hanahan D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812

Brankin B, Campbell M, Canning P, Gardiner TA, and Stitt AW. 2005. Endostatin modulates vegf-mediated barrier dysfunction in the retinal microvascular endothelium. Exp Eye Res 81:22-31

Brower V. 2000. Fit for reputation. Judah folkman counter-sued abbott in the legal battle over kringle 5. EMBO Rep 1:301-302

Cao R and Cao Y. 2010. Cancer-associated retinopathy: A new mechanistic insight on vascular remodeling. Cell Cycle 9:1882-1885

Cao R, Xue Y, Hedlund EM, Zhong Z, Tritsaris K, Tondelli B, Lucchini F, Zhu Z, Dissing S, and Cao Y. 2010. Vegfr1-mediated pericyte ablation links vegf and plgf to cancer-associated retinopathy. Proc Natl Acad Sci U S A 107:856-861

Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, and Nagy A. 1996. Abnormal blood vessel development and lethality in embryos lacking a single vegf allele. Nature 380:435-439

Celik I, Surucu O, Dietz C, Heymach JV, Force J, Hoschele I, Becker CM, Folkman J, and Kisker O. 2005. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65:11044-11050

Chang WG, Andrejczak JW, Kluger MS, Saltzman WM, and Pober JS. 2013. Pericytes modulate endothelial sprouting. Cardiovasc Res 100:492-500

Chavakis T, Athanasopoulos A, Rhee JS, Orlova V, Schmidt-Woll T, Bierhaus A, May AE, Celik I, Narwroth PP, and Preisner KT. 2005. Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment. Blood 105:1036-1043

Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, Song X, and Luo Y. 2011. Tumor-associated macrophages promote angiogenesis
and melanoma growth via adenomedullin in both paracrine and autocrine manners. Clin Cancer Res.
Chi SL and Pizzo SV. 2006. Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: A mechanism dependent on cell surface-associated ATP synthase. Cancer Res 66:875-882.
Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familietti PC, Pan YC, Olander JF, Connolly DT, and Stern D. 1990. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545.
Czepulch P, Olieslagers S, van Hulten R, Voo A, and Waltenberger J. 2011. Vegf-a-induced chemotaxis of cd16+ monocytes is decreased secondary to lower vegf-r1 expression. Atherosclerosis 215:331-338.
Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames KC, and Pezzella F. 2013. Vessel co-option in primary human Lewis lung carcinoma. Cell 88:801-810.
Dong Z, Kumar R, Yang X, and Fidler IJ. 1997. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88:801-810.
Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris AL, Gatter CL, and Brekken RA. 2008. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 68:4340-4346.
Distler O, Neidhart M, Gay RE, and Gay S. 2002. The molecular control of angiogenesis. Int Rev Immunol 21:33-49.
Dome B, Hendrix MJ, Paku S, Tovari J, and Timar J. 2007. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 170:1-15.
Dong Z, Kumar R, Yang X, and Fidler IJ. 1997. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88:801-810.
Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris AL, Gatter KC, and Pezzella F. 2013. Vessel co-option in primary human tumors and metastases: An obstacle to effective anti-angiogenic treatment? Cancer Med 2:427-436.
Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, and Senger DR. 1991. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 174:1275-1278.
Dvorak HF, Weaver VM, Tlsty TD, and Bergers G. 2011. Tumor microenvironment and progression. J Surg Oncol 103:468-474.
Fattin A, Herzog B, Mahmoud M, Yamaji M, Plein A, Denti L, Ruhrberg C, and Zachary I. 2014. Neuruplin 1 (nrp1) hypomorphism combined with defective vegf-a binding reveals novel roles for nrp1 in developmental and pathological angiogenesis. Development 141:556-562.
Fattin A, Schwarz Q, Davidson K, Normando EM, Denti L, and Ruhrberg C. 2011. The cytoplasmic domain of neuruplin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins. Development 138:4185-4191.
Fattin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Przykhozhij S, Peri F, Wilson SW, and Ruhrberg C. 2010. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of vegf-mediated endothelial tip cell induction. Blood 116:829-840.
Fattin A, Vieira JM, Plein A, Denti L, Fruttiger M, Pollard JW, and Ruhrberg C. 2013. Nrp1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis. Blood 121:2352-2362.
Ferrara N, Gerber HP, and LeCouter J. 2003. The biology of vegf and its receptors. Nat Med 9:669-676.
Fidler IJ. 2011. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21:107-112.
Fisher B, Gunduz N, Coyle J, Ruddock C, and Saffer E. 1989a. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 49:1996-2001.
Fisher B, Saffer E, Gunduz N, Coyle J, and Ruddock C. 1990. Serum growth factor following primary tumor removal and the inhibition of its production by preoperative therapy. Prog Clin Biol Res 354A:47-60.
Fisher B, Saffer E, Ruddock C, Coyle J, and Gunduz N. 1999b. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 59:2002-2004.
Folkman J. 1985. Angiogenesis and its inhibitors. Important Adv Oncol 42-62.
Folkman J. 1995. Angiogenesis inhibitors generated by tumors. Mol Med 1:120-122.
Folkman J. 2002. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18.
Folkman J. 2003. Angiogenesis inhibitors: A new class of drugs. Cancer Biol Ther 2: S127-133.
Folkman J and Ingber D. 1992. Inhibition of angiogenesis. Semin Cancer Biol 3:89-96.
Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, and Soff GA. 1997. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A 94:10868-10872.
Gimbrone MA, Jr., Leapman SB, Cotran RS, and Folkman J. 1973. Tumor angiogenesis: Iris neovascularization at a distance from experimental intraocular tumors. J Natl Cancer Inst 50:219-228.
Greenberg JI, Shields DJ, Barillas SG, Acvedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, and Cheresh DA. 2006. A role for vegf-a as a negative regulator of pericyte function and vessel maturation. Nature 456:809-813.
Grosskreutz CL, Anand-Apte B, Duplaa C, Quinn TP, Terman BI, Zetter B, and D’Amore PA. 1999. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res 58:128-136.
Gupta K and Zhang J. 2005. Angiogenesis: A curse or cure? Postgrad Med J 81:236-242.
Hanahan D and Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
Hanahan D and Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, and Hellberg C. 2007. Identification of a subset of pericytes that respond to combination therapy targeting pdgf and vegf signaling. Int J Cancer 121:2606-2614.
Ibrahim YF, Wong CM, Pavlickova L, Liu L, Trasar L, Bansal G, and Suzuki YJ. 2014. Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing. J Am Heart Assoc 3:e000520.
Indraccolo S. 2013. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors. Adv Exp Med Biol 734:37-52

Javaherian K, Lee TY, TJin Tham Sjin RM, Parris GE, and Hlatky L. 2011. Two endogenous antiangiogenic inhibitors, endostatin and angiostatin, demonstrate biphasic curves in their antitumor profiles. Dose Response 9:369-376

Jeong GS, Han S, Shin Y, Kwon GH, Kam MD, Lee SH, and Chung S. 2011. Sprouting angiogenesis under a chemical gradient regulated by interaction with endothelial monolayer in microfluidic platform. Anal Chem

Ji RC. 2011. Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis. Cell Mol Life Sci

Kenan DJ and Wahl ML. 2005. Ectopic localization of mitochondrial atp synthase: A target for anti-angiogenesis intervention? J Bioenerg Biomembr 37:461-465

Kiba A, Sagara H, Hara T, and Shibuya M. 2003a. Vegfr-2-specific ligand vegf-e induces non-edematous hyper-vascularization in mice. Biochem Biophys Res Commun 301:371-377

Kiba A, Yabana N, and Shibuya M. 2003b. A set of loop-1 and -3 structures in the novel vascular endothelial growth factor (vegf) family member, vegf-enz-7, is essential for the activation of vegfr-2 signaling. J Biol Chem 278:13453-13461

Koshida R, Ou J, Matsunaga T, Chilian WM, Oldham KT, Ackerman AW, and Pritchard KA, Jr. 2003. Angiostatin: A negative regulator of endothelial-dependent vasodilatation. Circulation 107:803-806

Lee JS, Chang SC, Pravda EA, Folkman J, Abdollahi A, and Javaherian K. 2009. Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood 114:1987-1998

Li C, Liu B, Dai Z, and Tao Y. 2011. Knockdown of vegf receptor-1 (vegf-r1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (ccrc). Cancer Biol Ther 12

Lin SL, Chang FC, Schrimpf C, Chen YT, Wu CF, Wu VC, Chiang WC, Kuhnert F, Kuo CJ, Chen YM, Wu KD, Tsai TJ, and Duffield JS. 2011. Targeting endothelium-pericyte cross talk by inhibiting vegf receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 178:911-923

Luo WY, Shih YS, Lo WH, Chen HR, Wang SC, Wang CH, Chien CH, Chiang CS, Chuang YJ, and Hu YC. 2011. Baculovirus vectors for angiogenesis-based cancer gene therapy. Cancer Gene Ther 18:637-645

Mariners AG, She H, Zambarakji H, Hashizume H, Connolly EJ, Kim I, Gragoudas ES, Miller JW, and Olsen BR. 2007. Endogenous endostatin inhibits chordal neovascularization. FASEB J 21: 3809-3818

Miquelot L, Langille BL, and Nagy A. 2000. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127:3941-3946

Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW, and Pizzo SV. 1999. Angiostatin binds atp synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 96:2811-2816

Motegi K, Harada K, Pazouki S, Baillie R, and Schor AM. 2002. Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis. Histochem J 34:411-421

O’Reilly MS. 1997. Angiostatin: An endogenous inhibitor of angiogenesis and of tumor growth. EXS 79:273-294

O’Reilly MS, Boehm T, Shing Y, Fukai N, Vastios G, Lane WS, Flynn E, Birchard JKE, Olsen BR, and Folkman J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285

O’Reilly MS, Holmgren L, Chen C, and Folkman J. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692

O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, and Folkman J. 1994. Angiostatin: A circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59:471-482

Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, Kraft PE, McDonald DM, and Blau HM. 2004. Microenvironmental vegf concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 113: 516-527

Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, and Kaipainen A. 2002. Ppar-gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923-932

Ramakrishnan S, Nguyen TM, Subramaniam IV, and Kelekar A. 2007. Autophagy and angiogenesis inhibition. Autophagy 3:512-515

Reynolds AR. 2010. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response 8:253-284

Ribatti D, Nicos B, and Crivellato E. 2011. The role of pericytes in angiogenesis and of tumor growth. EXS 79:273-294

Ryu S and Albert DM. 1979. Evaluation of tumor angiogenesis factor (tangf) activity in the rabbit cornea model. Invest Ophthalmol Vis Sci 18: 831-841

Saphir A. 1997. Angiogenesis: The unifying concept in cancer? J Natl Cancer Inst 89:1658-1659

Sciavocelli M, Gaude E, Hilvo M, and Frezza C. 2014. The metabolic alterations of cancer cells. Methods Enzymol 542:1-23

Senger DR, Perruzzi CA, Feder J, and Dvorak HF. 1986. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629-5632

Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Bense B, Jackman RW, Dvorak AM, and Dvorak HF. 1993. Vascular permeability factor (vpf, vegf) in tumor biology. Cancer Metastasis Rev 12:303-324

Shyong MP, Lee FL, Kuo PC, Wu AM, Cheng HC, Chen SL, Tung TH, and Tsao YP. 2007. Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adenovirus vector. Mol Vis 13:133-141
Sima J, Zhang SX, Shao C, Fant J, and Ma JX. 2004. The effect of angiostatin on vascular leakage and vegf expression in rat retina. FEBS Lett 564:19-23

Slaton JW, Perrotte P, Inoue K, Dinney CP, and Fidler IJ. 1999. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5: 2726-2734

Springer ML, Ozawa CR, Banfi A, Kraft PE, Ip TK, Brazelton TR, and Blau HM. 2003. Localized arteriole formation directly adjacent to the site of vegf-induced angiogenesis in muscle. Mol Ther 7:441-449

Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murтомaki A, Aranda E, Miura N, Yla-Herttuala S, Fruttiger M, Makinen T, Eichmann A, Pollard JW, Gerhardt H, and Alitalo K. 2011. Vegfr-3 controls tip to stalk conversion at vessel fusion sites by reinforcing notch signalling. Nat Cell Biol 13:1202-1213

Tarui T, Miles LA, and Takada Y. 2001. Specific interaction of angiostatin with integrin alpha(v) beta(3) in endothelial cells. J Biol Chem 276:39562-39568

Tijn Tham Sjin RM, Naspinski J, Birsner AE, Li C, Chan R, Lo KM, Gillies S, Zurakowski D, Folkman J, Samulski J, and Javaherian K. 2006. Endostatin therapy reveals a u-shaped curve for antitumor activity. Cancer Gene Ther 13:619-627

Troyanovsky SB, Levchenko T, Mansson G, Matvijenko O, and Holmgren L. 2001. Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152:1247-1254

Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serne EH, Lammertsma AA, and Smit EF. 2012. Rapid decrease in delivery of chemotherapy to tumors after anti-vegf therapy: Implications for scheduling of anti-angiogenic drugs. Cancer Cell 21:82-91

von Degenfeld G, Banfi A, Springer ML, Wagner RA, Jacobi J, Ozawa CR, Merchant MJ, Cooke JP, and Blau HM. 2006. Micro-environmental vegf distribution is critical for stable and functional vessel growth in ischemia. FASEB J 20:2657-2659

Wahl ML, Kenan DJ, Gonzalez-Gronow M, and Pizzo SV. 2005. Angiostatin’s molecular mechanism: Aspects of specificity and regulation elucidated. J Cell Biochem 96:242-261

Wajih N and Sane DC. 2003. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood 101:1857-1863

Weis SM. 2011. Evaluation of vegf-induced vascular permeability in mice. Methods Mol Biol 763:403-415

Wu SY, Lan SH, Cheng DE, Chen WK, Shen CH, Lee YR, Zuchini R, and Liu HS. 2011. Ras-related tumorigenesis is suppressed by bnip3-mediated autophagy through inhibition of cell proliferation. Neoplasia 13:1171-1182

Wynn TA. 2008. Cellular and molecular mechanisms of fibrosis. J Pathol 214:199-210

Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S, Tanaka N, and Yamamoto H. 1999. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 79:501-509

Yamamoto K, Shimizu N, Obi S, Kumagaya S, Taketani Y, Kamiya A, and Ando J. 2007. Involvement of cell surface atp synthase in flow-induced atp release by vascular endothelial cells. Am J Physiol Heart Circ Physiol 293: H1646-1653

Zhao W, Jiang AH, Li CY, Yang WZ, Xu CC, and Liu ZG. 2007. Pericytes are correlated with the permeability of rat corneal neovascular vessels induced by alkali burn. Chin Med J (Engl) 120: 274-279